Phase 1/2 Multi-Center Study to Evaluate the Safety and Efficacy of ONCT-808 in Adult Subjects With Relapsed or Refractory Aggressive B-Cell Malignancies

Description

This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.Study ONCT-808-101 is a Phase 1/2, single-arm, open-label, multi-center study to evaluate the safety and tolerability, pharmacokinetics, and anti-tumor activity of ONCT-808 in subjects with aggressive B cell lymphoma (BCL), including large B-cell lymphoma (LBCL) and mantle cell lymphoma (MCL). The study will be separated into two distinct phases designated as Phase 1 and Phase 2. After the safety and tolerability of ONCT-808 have been assessed to select the recommended Phase 2 dose (RP2D) in Phase 1, Phase 2 will commence to further validate the dose and evaluate the safety and efficacy of ONCT-808. In Phase 2, subjects with LBCL or MCL will be enrolled into 2 separate dose expansion cohorts.

Trial Eligibility

Key Inclusion Criteria: * Over 18 years old * Histologically confirmed aggressive B-cell NHL, including: * MCL, with diagnosis confirmed by cyclin D1 overexpression or evidence of t (11;14) translocation * LBCL, including: * DLBCL NOS * Primary mediastinal LBCL * High-grade BCL * DLBCL arising from follicular lymphoma * Follicular lymphoma grade 3B * Richter's syndrome * Availability of archival tissue for immunohistology, or willing to undergo baseline biopsy if not available * R/R with no available therapy. Subject must have: * Received prior systemic therapy that has included an alkylating agent, anthracycline, and an anti-CD20 mAb * Received and progressed after autologous hematopoietic stem cell transplant (HSCT) or is ineligible for or has refused to receive HSCT * Received prior approved CD19 CAR T-cell therapy or is ineligible for or has refused CD19 CAR-T * Minimum washout period between previous systemic therapy and leukapheresis includes: * Chemotherapy: at least 14 days or 5 half-lives, whichever is shorter * Autologous HSCT: at least 3 months * CD19 CAR T-cell therapy: at least 6 months * ≥1 measurable lesion per Lugano criteria (Cheson, 2014) * Subject has Fluorodeoxyglucose (FDG)-avid disease. * Subject has an ECOG performance status of 0 or 1. * Subject has adequate organ function: * ALC ≥100/uL * ANC ≥1000/uL (≥500/uL if due to lymphoma; growth factors allowed) * Hgb ≥8 g/dL (transfusion allowed) * Platelets ≥75,000/uL (≥50,000/uL if due to lymphoma; transfusion allowed) * CrCL ≥50 ml/min; AST/ALT ≤2.5x ULN, T. bili ≤1.5 mg/dl (except Gilbert's) * EF ≥50% by ECHO/MUGA; NCS ECG, NCS pleural effusion; O2 sat \>92% * Subject has an estimated life expectancy of \>12 weeks Key Exclusion Criteria: * Prior ROR1-targeted therapy * Current or anticipated systemic immunosuppressive therapy (e.g., prednisone \>5 mg) from LD chemo until Day 28 post ONCT-808 dosing * If receiving anticoagulation therapy, subject is unable to hold therapy for 3 days prior and 28 days following ONCT-808 administration * Known CNS involvement by malignancy within 6 months * H/o or current CNS disorder (e.g., seizure, CVA, dementia, cerebellar disease, cerebral edema, posterior reversible encephalopathy syndrome or any autoimmune disease with CNS involvement) within 6 months of study entry * Clinically significant cardiovascular disease (e.g., MI, UA, CABG, or CHF grade ≥2 NYHA within 12 months of planned ONCT-808 dosing) or serious arrhythmia requiring medication * Evidence of HIV infection or active HBV, HCV * Systemic fungal infection requiring medication in the last 12 months * H/o Covid-19 infection with residual lung infiltrate/fibrosis * H/o other malignancy except non-melanoma skin cancer or carcinoma in situ not in remission for ≥2 years * H/o autoimmune disease resulting in end organ injury or require systemic immunosuppression within last 2 years * H/o allogeneic HSCT or organ transplant

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.